New hope for aggressive breast cancer: trial tests powerful drug combo before surgery
NCT ID NCT07342283
Summary
This study is testing whether adding a new immunotherapy drug called QL1706 to standard chemotherapy works better when given before surgery for triple-negative breast cancer. It will involve 30 patients with stage II or III cancer who have not yet started treatment. The main goal is to see if this combination can completely eliminate the cancer from the breast and lymph nodes by the time of surgery.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER (TNBC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Affiliated Hospital of Nantong University
RECRUITINGNantong, Jiangsu, China
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.